Literature DB >> 15355480

Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients.

A Matucci1, P Parronchi, A Vultaggio, O Rossi, F Brugnolo, E Maggi, S Romagnani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15355480     DOI： 10.1111/j.1398-9995.2004.00532.x

Source DB:  PubMed          Journal:  Allergy        ISSN： 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  4 in total

1.  Risk of hospitalization for angio-oedema among users of newer COX-2 selective inhibitors and other nonsteroidal anti-inflammatory drugs.

Authors:  Amy Downing; Jacob Jacobsen; Henrik T Sorensen; Joseph K McLaughlin; Soren P Johnsen
Journal:  Br J Clin Pharmacol       Date:  2006-08-30       Impact factor: 4.335

2.  Tolerance to etoricoxib in children with nonsteroidal anti-inflammatory drug hypersensitivity.

Authors:  Wenyin Loh; Hwee Hoon Lim; Rajeshwar Rao; Anne Goh; Lin Xin Ong; Wen Chin Chiang
Journal:  Asia Pac Allergy       Date:  2015-01-28

3.  A novel phenotype of nonsteroidal anti-inflammatory drug hypersensitivity: the high-risk patient.

Authors:  Mario Sánchez-Borges; Arnaldo Capriles-Hulett; Fernan Caballero-Fonseca
Journal:  World Allergy Organ J       Date:  2009-02       Impact factor: 4.084

Review 4.  Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature.

Authors:  Tobias Bernd Weberschock; Sylke-Monina Müller; Sandra Boehncke; Wolf-Henning Boehncke
Journal:  Arch Dermatol Res       Date:  2007-05-11       Impact factor: 3.017
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.